The Latest Breaking News from MRK

The U.S. Food and Drug Administration (FDA) on Friday approved Merck Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for Keytruda.

On Friday, a European agency adopted two positive opinions for Merck Co. Inc.’s (NYSE:MRK) Keytruda (pembrolizumab).

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.

The U.K. faces a growing risk of losing pharmaceutical investment. That’s according to Oxford professor John Bell, a scientist who was involved in coordinating government and industry efforts during the COVID-19 vaccine rollout.

Merck Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Conference.

The U.S. Food and Drug Administration (FDA) on Thursday granted Breakthrough Therapy designation to Eli Lilly and Co.’s (NYSE:LLY) olomorasib, in combination with Merck Co. Inc.’s (NYSE:MRK) anti-PD-1 therapy Keytruda (pembrolizumab), for the first-line treatment of unresectable advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation…

Merck Co. Inc. (NYSE:MRK) on Tuesday shared topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance).

As Merck has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

On Tuesday, Merck  Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.

Despite Merck’s underperformance relative to the broader market over the past year, analysts continue to maintain fair confidence regarding its future potential.

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 billion cost-cutting plan and a $10 billion push into new therapies —moves that analysts say could revive the shares if executed well.